1
Participants
Start Date
May 31, 2010
Primary Completion Date
November 30, 2010
HQK-1004
1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
Valganciclovir (may substitute with ganciclovir)
900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
Weill Cornell Medical College, New York
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Northwestern University Feinberg School of Medicine, Chicago
Washington University School of Medicine, St Louis
Feigin Center - Center for Cell and Gene Therapy, Houston
University of California, San Francisco, San Francisco
LPCH/Stanford, Palo Alto
Hackensack University Medical Center, Hackensack
Lead Sponsor
HemaQuest Pharmaceuticals Inc.
INDUSTRY